Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Ovarian Neoplasms 2Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Oligodendroglioma 1Melanoma 1Lung Neoplasms 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Carcinoma 1Astrocytoma 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Temozolomide 94Radiotherapy 59Bevacizumab 59Radiosurgery 41Carboplatin 27Irinotecan 26Magnetic Resonance Spectroscopy 25Surgical Procedures, Operative 23Etoposide 22Carmustine 20Filgrastim 18Erlotinib Hydrochloride 17Cyclophosphamide 16Cisplatin 16Vincristine 15Lomustine 15Lapatinib 15Sorafenib 13Radiation 13Trastuzumab 12Nivolumab 12Imatinib Mesylate 12Thalidomide 11Surveys and Questionnaires 11Granulocyte Colony-Stimulating Factor 11Radiotherapy, Intensity-Modulated 10Aminolevulinic Acid 10temsirolimus 9Topotecan 9Thiotepa 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Brain Neoplasms × cositecan × Clear all
NCT00062478 2020-03-12

Study of Karenitecin (BNP1350) in Patients With Brain Tumors

BioNumerik Pharmaceuticals, Inc.

Phase 2 Completed
40 enrolled
CNS

Brain Neoplasms

NCT00014521 2008-07-24

Karenitecin in Treating Patients With Recurrent Malignant Glioma

National Cancer Institute (NCI)

Phase 1 Completed
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡